KeyMed Biosciences Inc
HKEX:2162
Intrinsic Value
Keymed Biosciences, Inc. is an investment holding company. [ Read More ]
The intrinsic value of one KeyMed Biosciences Inc stock under the Base Case scenario is hidden HKD. Compared to the current market price of 36.2 HKD, KeyMed Biosciences Inc is hidden .
Valuation Backtest
KeyMed Biosciences Inc
Run backtest to discover the historical profit from buying and selling KeyMed Biosciences Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
KeyMed Biosciences Inc
| Current Assets | 2.9B |
| Cash & Short-Term Investments | 2.7B |
| Receivables | 79.6m |
| Other Current Assets | 140.8m |
| Non-Current Assets | 943.4m |
| Long-Term Investments | 21.6m |
| PP&E | 910.9m |
| Intangibles | 1.1m |
| Other Non-Current Assets | 9.7m |
| Current Liabilities | 314.2m |
| Accounts Payable | 29.5m |
| Accrued Liabilities | 110.3m |
| Other Current Liabilities | 174.4m |
| Non-Current Liabilities | 582.4m |
| Long-Term Debt | 353.5m |
| Other Non-Current Liabilities | 229m |
Earnings Waterfall
KeyMed Biosciences Inc
|
Revenue
|
354.1m
CNY
|
|
Cost of Revenue
|
-36.9m
CNY
|
|
Gross Profit
|
317.2m
CNY
|
|
Operating Expenses
|
-750.8m
CNY
|
|
Operating Income
|
-433.6m
CNY
|
|
Other Expenses
|
74.3m
CNY
|
|
Net Income
|
-359.4m
CNY
|
Free Cash Flow Analysis
KeyMed Biosciences Inc
Profitability Score
Profitability Due Diligence
KeyMed Biosciences Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
KeyMed Biosciences Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
KeyMed Biosciences Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
KeyMed Biosciences Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
KeyMed Biosciences Inc
According to Wall Street analysts, the average 1-year price target for KeyMed Biosciences Inc is 61.96 HKD with a low forecast of 53.53 HKD and a high forecast of 81.9 HKD.
Shareholder Return
Price
KeyMed Biosciences Inc
| Average Annual Return | 7.3% |
| Standard Deviation of Annual Returns | 83.11% |
| Max Drawdown | -75% |
| Market Capitalization | 10.1B HKD |
| Shares Outstanding | 276 604 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Keymed Biosciences, Inc. is an investment holding company. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.
Contact
IPO
Employees
Officers
The intrinsic value of one KeyMed Biosciences Inc stock under the Base Case scenario is hidden HKD.
Compared to the current market price of 36.2 HKD, KeyMed Biosciences Inc is hidden .
You don't have any saved screeners yet
